Jun Kawashima - Concepedia

Author

Jun Kawashima

Princess Margaret Cancer Centre ORCID

Also Known As

J KAWASHIMA, J Kawashima, J. Kawashima, JUN KAWASHIMA, JUNZO KAWASHIMA, Jun KAWASHIMA, Jun Kawashima

159

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Princess Margaret Cancer Centre The University of Texas MD Anderson Cancer Center Guy's and St Thomas' NHS Foundation Trust Gilead Sciences (United States)Université Paris Cité

About

Jun Kawashima is an author at Princess Margaret Cancer Centre specializing in medicine, pharmacotherapy, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	577
2	Health Sciences	2	2	37
3	Gastroenterology	1	1	19
4	Hepatology	1	1	19
5	Immunology	1	1	22

Jun Kawashima

Publications

Citations

H-Index

Page 1

	Year	Citations
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker, The Lancet Haematology Hematological MalignancyMomelotinib VersusSimplify 2HematologyPharmacotherapy	2017	301
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, The Lancet Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolSymptomatic PatientsHematology	2023	164
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, Blood Advances	2020	119
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis Vikas Gupta, Ruben A. Mesa, Michael W. Deininger, Haematologica	2016	94
Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis Animesh Pardanani, Jason Gotlib, Vikas Gupta, Blood	2013	44
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials Srđan Verstovšek, Ruben A. Mesa, Vikas Gupta, Blood Advances	2023	44
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study Aaron T. Gerds, Srđan Verstovšek, Alessandro M. Vannucchi, The Lancet Haematology Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolRandomised Phase 3Hematology	2023	33
Antitumor activity of heptelidic acid chlorohydrin. Jun Kawashima, FUMI ITO, Takashi Kato, The Journal of Antibiotics Medicinal ChemistryAntitumor ActivityMedicinePharmacotherapyAnti-cancer Agent	1994	23
Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis Animesh Pardanani, Jason Gotlib, Vikas Gupta, Blood	2012	22
Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non–Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure David A. Barbie, Alexander I. Spira, Karen Kelly, Clinical Lung Cancer	2018	22

Page 1